Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU

Enterprise Technology

2 articles

Snowflake BUILD London Showcases Cloud AI Battle for European Enterprise Customers

Snowflake BUILD London Showcases Cloud AI Battle for European Enterprise Customers

Snowflake's BUILD London 2026 conference demonstrated AI capabilities including Cortex functions and agent evaluations as cloud providers compete for European enterprise adoption. HSBC and Lloyds represent financial institutions migrating to cloud AI platforms. Analysts signal continued AI infrastructure investment with Wolfe Research naming Nvidia top pick and Morgan Stanley raising ASML targets 40%.

ViaNews Editorial Team (Europe)•
Snowflake Launches AI Development Suite in London as European Financial Services Accelerate Cloud AI Adoption

Snowflake Launches AI Development Suite in London as European Financial Services Accelerate Cloud AI Adoption

Snowflake unveiled production-ready AI tools at BUILD London 2026, including Cortex AI Functions, Notebooks GA, and Agent Evaluations, targeting European enterprises in regulated sectors. The launch mirrors aggressive AI platform expansions by AWS Bedrock, Google Cloud Vertex AI, and Azure AI as cloud vendors compete for enterprise AI workloads. European financial institutions including HSBC, BNP Paribas, and Citigroup are early adopters of embedded agentic capabilities.

ViaNews Editorial Team (Europe)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com